+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 65Years
All Genders
ID06830044

Randomized Double-Blind Study Evaluating Milsaperidone as Add-On Therapy for Major Depressive Disorder

Led by Vanda Pharmaceuticals · Updated on 2026-09-24

500

Participants Needed

53

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of milsaperidone as an add-on treatment for patients with Major Depressive Disorder MDD who have not responded adequately to current antidepressant therapy. This phase 3, randomized, double-blind, placebo-controlled study aims to compare milsaperidone with a placebo to better understand its potential benefits and risks in this patient population. Participants will be randomly assigned to receive either oral milsaperidone or a matching placebo. The study uses a parallel design and involves multiple centers. The treatment period lasts 6 weeks, during which participants take the assigned oral medication as adjunctive therapy to their existing antidepressant regimen. During the study, participants will be closely monitored with regular assessments including the Montgomery-Asberg Depression Rating Scale MADRS to measure changes in depressive symptoms from baseline. Safety and tolerability will also be evaluated throughout the trial. The total duration of participation corresponds with the 6-week treatment and ongoing safety assessments, concluding by March 2028.

CONDITIONS

Brief Title

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Research Team

V

Vanda Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here